泰恩康 (301263)
Guangdong Taienkang Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 42549.75
- Circulating A-Shares(W): 30358.61
- Earnings Per Share(RMB): 0.0700
- Net Assets Per Share(RMB): 4.0757
- Operating Revenue(W RMB): 52582.83
- Total Profit(W RMB): 1966.61
- Net Profit Attributable to Parent(W RMB): 3140.52
- Net Profit Growth Rate(%): -73.00
- Weighted Return on Equity(%): 1.7900
- Operating Cash Flow Per Share(RMB): -0.1540
- Undistributed Profit Per Share(RMB): 0.7853
- Capital Reserve Per Share(RMB): 2.1560
2. Main Business
The main business covers:
- Sexual health drugs
- Gastrointestinal drugs
- Ophthalmic drugs
3. Company Basic Information
- Company Name: Guangdong Taienkang Pharmaceutical Co., Ltd.
- Listing Date: 2022-03-29
- Industry: Pharmaceutical Business (Tongdaxin Research Industry)
- Address: Building A, No. 8 Wanjinan Erjie, Taishan North Road, Longhu District, Shantou City, Guangdong Province, China
- Website: www.tai-kang.com.cn
- Company Profile: On October 27, 2011, the shareholders' meeting of the limited company resolved to approve the overall change of the limited company into a joint-stock company. The specific conversion plan was: based on the audited net assets of the limited company of RMB 98,970,940.34 as of August 31, 2011, as per the audit report "Jing Yong Shen Zi [2011] No. 14003", it was converted into 67,500,000 shares with a par value of RMB 1.00 per share. The remaining amount of RMB 31,470,940.34 after conversion was recorded into capital reserve. The original shareholders of the limited company held corresponding proportions of shares in the joint-stock company according to their respective shareholding ratios.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Guotai Junan Securities Asset Management - Guotai Junan Private Client Exclusive FOF1571 Single Asset Management Plan - Junan Asset Management Junde 3481 Single Asset Management Plan | Asset Management Plan | 643.57 | 2.12 |
| 2 | Basic Pension Fund 1203 Portfolio | Social Security Fund | 585.27 | 1.93 |
| 3 | Shaanxi International Trust Co., Ltd. - Shaanxi Trust · Taienkang 2025 Employee Shareholding Collective Fund Trust Plan | Asset Management Plan | 539.62 | 1.78 |
| 4 | Penghua High-Quality Growth Hybrid Securities Investment Fund Class A | Fund | 276.18 | 0.91 |
| 5 | Dacheng Active Growth Hybrid Securities Investment Fund Class A | Fund | 183.90 | 0.61 |
| 6 | Dacheng Value Growth Securities Investment Fund Class A | Fund | 134.95 | 0.44 |
| 7 | Dacheng Consumption Theme Hybrid Securities Investment Fund Class A | Fund | 121.81 | 0.40 |
| 8 | Penghua Steady Return Hybrid Securities Investment Fund Class A | Fund | 104.00 | 0.34 |
| 9 | Dacheng Jingyang Leading Hybrid Securities Investment Fund Class A | Fund | 80.28 | 0.26 |
| 10 | Dacheng Domestic Demand Growth Hybrid Securities Investment Fund Class A | Fund | 35.03 | 0.12 |
5. Concept Sectors
- Mask Protection
- Innovative Drugs
- Weight Loss Drugs
- Synthetic Biology
- Margin Trading
- High P/E Ratio
- ChiNext 300
- ChiNext Pharmaceuticals
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information